MiniTEM - designed for nanoparticle characterization (brochure dec 2017)

Document -

MiniTEM - designed for nanoparticle characterization (brochure dec 2017)

go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.pdf
Download

Topics

  • Pharmacy

Categories

  • vironova
  • minitem

Contacts

Related media

  • Automated integrity analysis of AAV and Adenovirus particles using MiniTEM™ (white paper)
    Automated integrity analysis of AAV and Adenovirus particles using MiniTEM™ (white paper)
    License:
    Media Use
    File format:
    .pdf
    more info...
    Download
  • A comparative study of MiniTEM™ versus DLS Zetasizer Nano and NTA NanoSight NS300 (white paper)
    A comparative study of MiniTEM™ versus DLS Zetasizer Nano and NTA NanoSight NS300 (white paper)
    License:
    Media Use
    File format:
    .pdf
    more info...
    Download

Related content

  • MiniTEM™ for quality analysis of phage preparations - poster presentation at the Phage Future Congress 2019

    At the Phage Futures Congress in Washington D.C. experts from regulatory bodies, pharmaceutical companies and government institutions will discuss how to actively progress clinical science and viable phage application routes to market. Vironova represenatives will have a poster presentation to show the potential of MiniTEM™, our desktop low-voltage (25 keV) transmission electron microscope.

  • MiniTEM contributes to the success of our customers

    ​The event at Cell & Gene Therapy in Amsterdam this week was a successful showcase for MiniTEM. Apart from our own activities at our booth and a presentation in the main program we also received an excellent testimonial

Enter your email address to follow Vironova AB (publ)

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Vironova AB (publ).

Okay